Education
About Us
Working with TipRanks
Follow Us
Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
Total Valuation
Benitec Biopharma has a market cap or net worth of $420.01M. The enterprise value is $245.54M.
Market Cap$420.01M
Enterprise Value$245.54M
Share Statistics
Benitec Biopharma has 26,250,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,250,470
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Benitec Biopharma’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -45.97%.
Return on Equity (ROE)-0.46
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-45.97%
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee13.50K
Profits Per Employee-1.36M
Employee Count16
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Benitec Biopharma is -5.42. Benitec Biopharma’s PEG ratio is -0.76.
PE Ratio-5.42
PS Ratio0.00
PB Ratio5.38
Price to Fair Value2.50
Price to FCF-18.63
Price to Operating Cash Flow-28.12
PEG Ratio-0.76
Income Statement
In the last 12 months, Benitec Biopharma had revenue of 216.00K and earned -21.75M in profits. Earnings per share was -2.68.
Revenue216.00K
Gross Profit108.00K
Operating Income-22.49M
Pretax Income-22.37M
Net Income-21.75M
EBITDA-22.49M
Earnings Per Share (EPS)-2.68
Cash Flow
In the last 12 months, operating cash flow was -18.67M and capital expenditures -18.00K, giving a free cash flow of -18.69M billion.
Operating Cash Flow-18.67M
Free Cash Flow-18.69M
Free Cash Flow per Share-0.71
Dividends & Yields
Benitec Biopharma pays an annual dividend of $0.51, resulting in a dividend yield of ―
Dividend Per Share$0.51
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.73
52-Week Price Change118.22%
50-Day Moving Average13.80
200-Day Moving Average11.64
Relative Strength Index (RSI)64.95
Average Volume (3m)40.43K
Important Dates
Benitec Biopharma upcoming earnings date is Sep 25, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateSep 25, 2025
Ex-Dividend DateJun 01, 2018
Financial Position
Benitec Biopharma as a current ratio of 10.49, with Debt / Equity ratio of 0.98%
Current Ratio10.49
Quick Ratio10.49
Debt to Market Cap0.00
Net Debt to EBITDA2.25
Interest Coverage Ratio-24.88
Taxes
In the past 12 months, Benitec Biopharma has paid -619.00K in taxes.
Income Tax-619.00K
Effective Tax Rate0.03
Enterprise Valuation
Benitec Biopharma EV to EBITDA ratio is -2.99, with an EV/FCF ratio of -3.44.
EV to Sales311.69
EV to EBITDA-2.99
EV to Free Cash Flow-3.44
EV to Operating Cash Flow-3.47
Balance Sheet
Benitec Biopharma has $103.58M in cash and marketable securities with $959.00K in debt, giving a net cash position of -$102.62M billion.
Cash & Marketable Securities$103.58M
Total Debt$959.00K
Net Cash-$102.62M
Net Cash Per Share-$3.91
Tangible Book Value Per Share$2.91
Margins
Gross margin is 0.00%, with operating margin of -10412.04%, and net profit margin of -10069.91%.
Gross Margin0.00%
Operating Margin-10412.04%
Pretax Margin-10356.48%
Net Profit Margin-10069.91%
EBITDA Margin-10412.04%
EBIT Margin-10069.91%
Analyst Forecast
The average price target for Benitec Biopharma is $24.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$24.50
Price Target Upside51.52% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast83.98%